Get access

Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient with dilated cardiomyopathy

Authors

  • Aliakbar Zeinaloo,

    1. Department of Pediatrics, Pediatric Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
    Search for more papers by this author
  • Keyhan S. Zanjani,

    1. Department of Pediatrics, Pediatric Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
    Search for more papers by this author
  • Mohammad M. Bagheri,

    1. Department of Pediatrics, Pediatric Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
    Search for more papers by this author
  • Mandana Mohyeddin-Bonab,

    1. Department of Pediatrics, Pediatric Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
    Search for more papers by this author
  • Maryam Monajemzadeh,

    1. Department of Pediatrics, Pediatric Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
    Search for more papers by this author
  • Mohammad H. Arjmandnia

    1. Immunogenetics Laboratory, Department of Immunology, Tehran University of Medical Sciences, Tehran, Iran
    Search for more papers by this author

  • No conflict of interest is reported. No financial support is received.

Keyhan S. Zanjani, Children’s Medical Center, 62 Dr Gharib St., 14194 Tehran, Iran
Tel.: +98 21 88687276
Fax: +98 21 88687276
E-mail: sayadpour@tums.ac.ir

Abstract

Zeinaloo AA, Zanjani KS., Bagheri MM., Mohyeddin-Bonab M, Monajemzadeh M, Arjmandnia MH. Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient with dilated cardiomyopathy.
Pediatr Transplantation 2011: 15: E183–E186. © 2011 John Wiley & Sons A/S.

Abstract:  Relatively high prevalence of dilated cardiomyopathy in children, unfavorable response to traditional drug therapy, and limitations in heart transplantation call for new therapeutic options. Stem cell therapy can be promising in children suffering from this disease. The presented case documents that intracoronary injection of autologous bone marrow-derived mesenchymal stem cells in a boy with progressive dilated cardiomyopathy is feasible and safe. Furthermore, it may positively influence functional class, quality of life, and echocardiographic indices of cardiac function.

Get access to the full text of this article

Ancillary